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by T Cells and TNF-Regulated Genes Linked to
Psoriasis Transcriptome
Asifa S. Haider1, Jules Cohen1, Ji Fei2, Lisa C. Zaba1, Irma Cardinale1, Kikuchi Toyoko1, Jurg Ott2 and
James G. Krueger1
Therapeutic antibodies against tumor necrosis factor (TNF) (infliximab) and IFNg (fontolizumab) have been
developed to treat autoimmune diseases. While the primary targets of these antibodies are clearly defined, the
set of inflammatory molecules, which is altered by use of these inhibitors, is poorly understood. We elucidate
the target genes of these antibodies in activated human peripheral blood mononuclear cells from healthy
volunteers. While genes suppressed by fontolizumab overlap with known IFNg-induced genes, majority of
genes suppressed by infliximab have previously not been traced to TNF signaling. With this approach we were
able to extrapolate new TNF-associated genes to be upregulated in psoriasis vulgaris, an ‘‘autoimmune’’ disease
effectively treated with TNF antagonists. These genes represent potential therapeutic targets of TNF antagonists
in psoriasis. Furthermore, these data establish an unexpected effect of TNF blockade on IFNg synthesis by
T cells. Synthesis of IFNg, a cytokine of Th1-polarized T cells, is suppressed by 8.1-fold (Po0.01) at the mRNA
level, while synthesis of IFNg is eliminated in460% of individual T cells. These data suggest that TNF blockade
with infliximab can suppress a major pathway of the adaptive immune response and this observation provides a
key rationale for targeting TNF in ‘‘Type-1’’ T-cell-mediated autoimmune diseases.
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INTRODUCTION
Cytokines like tumor necrosis factor (TNF) and IFNg are key
regulators of cellular immune reactions in both normal
immune responses and autoimmune diseases. Some diseases,
for example, psoriasis, rheumatoid arthritis, or inflammatory
bowl disease, are effectively treated with cytokine inhibitors
like infliximab (Remicades), an anti-TNF antibody, or
etanercept (Enbrels), a fusion protein that binds to TNF and
lymphotoxin alpha (LTA) (Jacobi et al., 2003; Gottlieb et al.,
2005). The anti-IFNg antibody, fontolizumab (HuZAFTM), is
currently being tested in a phase 2 clinical trial for
rheumatoid arthritis. Psoriasis also shows a strong genomic
signature of IFNg-regulated genes (Lew et al., 2004),
suggesting that IFNg blockage might also produce therapeutic
benefits in this disease.
Cytokines like TNF and IFNg largely regulate immune
responses by acting as inducers of inflammatory gene
products. Through receptors on target cells, secreted TNF
activates NF-kB, whereas secreted IFNg activates STAT1,
which then increases transcription of a large group of
immunity-related genes (Boehm et al., 1997; Watts, 2005).
While TNF inhibitors are in widespread clinical use, very
little is known about the molecular and cellular effects of
cytokine blockade in human tissues.
At least one problem with detailed study of anti-
inflammatory mechanisms of TNF inhibitors is that the array
of genes regulated by TNF in leukocytes is largely unknown.
In contrast, IFNs have been much better studied with respect
to their ability to induce transcription of inflammation related
genes, and a set of B150 IFNg-regulated genes have been
codified and established from many independent research
studies (Boehm et al., 1997).
In most previous experiments, gene sets regulated by
proinflammatory cytokines have been identified by exposing
resting cells to single cytokines or to defined cytokine
mixtures (Banno et al., 2003). However, this does not model
therapeutic use of cytokine inhibitors in inflammatory
diseases, since activation of cells within mixed cell popula-
tions is ongoing at the time inhibitors are administered.
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Furthermore, immune reactions are known to be regulated by
varying ratios of cytokines made in complex mixtures during
cellular immune responses.
In this report, we present an approach to elucidate how
genes expressed in mixtures of activated mononuclear
leukocytes (T cells, B cells, and natural killer (NK) cells)
may be regulated by blocking TNF or IFNg with neutralizing
antibodies specific for these cytokines. These TNF- and IFNg-
regulated genes further served to re-evaluate the genes
known to be expressed in psoriasis vulgaris. IFN blockade
suppresses (by 41.5-fold) expression of 19 genes (most
previously identified as IFN-regulated in other cell types),
whereas TNF blockade suppresses (by 41.5-fold) expression
of 50 genes and most of these genes have not previously been
identified as being TNF regulated. The new insight into TNF-
regulated gene products not only helps to identify a larger
TNF signature in psoriasis (a common ‘‘autoimmune’’ disease
in humans), but also a strong interaction between TNF and
function of Th1 T cells in the adaptive immune system.
RESULTS
Analysis of genes induced by T-cell activation in peripheral
blood mononuclear cells versus purified T cells
T lymphocytes were activated by co-ligation of CD3 and
CD28 with bead-bound antibodies, using either purified T
cells (prepared by negative selection) or T cells contained in a
mixture of peripheral blood mononuclear cells (PBMCs).
From past work with analysis of cytokines produced by T
cells using intracellular staining and flow cytometry detec-
tion, both methods yielded activated T cells (confirmed by
increased CD69 expression) that produce high levels of TNF
and IFNg (Figure S1). Since secreted cytokines may regulate
gene transcription in cells other than T cells, we reasoned that
genes induced in PBMC preparations might be more
representative of cytokine-regulated genes in inflammatory
diseases, where complex mixtures of leukocytes are present
at sites of inflammation.
T-cell activation stimulated by ligation of CD3 and CD28
is shown in Figure 1, along with experimental conditions
where IFNg is blocked by incubation with fontolizumab, or
TNF is blocked by incubation with infliximab. A strong T-cell
activation response to CD3/CD28 ligation is shown by
upregulation of CD69 in 480% of CD3þ T cells (Figure 1a),
by an increase in annexinVþ and annexinVþ /propidium
iodideþ T cells (activation-induced apoptosis/cell death; Figure
1b), and by induction of IFNg synthesis in a subset of T cells
(Figure 1c). As discussed in more detail later, the conditions of
IFNg or TNF blockade with antibodies do not grossly alter T-cell
activation response (CD69 induction; Figure 1a) or overall
levels of apoptosis/cell death (annexinV and propidium iodide
staining; Figure 1b). In fact, we did not detect any significant
effects on total CD3þ T cells, B cells, or NK cells (Figure 1d).
Figure 2 shows representative data of gene expression in
PBMCs that were cultured for 24 hours with or without T cell
stimulated by CD3/CD28 antibodies. We detected a large set
of genes (41,200) whose expression increased by 1.2-fold in
a statistically significant manner in activated PBMCs (see
Table 1 for a short list and Table S1 for a complete list of these
genes, while a subset is illustrated in the heat maps in
Figure 2). The number of activation-induced genes in PBMCs
was larger (571 genes) than genes induced in purified T-cell
cultures (487 genes), which could reflect regulation of T-cell
genes by accessory cells (Table S2). However, by comparing
how ‘‘pure’’ T-cell genes related to genes induced in PBMC
preparations (Table S2), it is clear that activated PBMCs
contain a mixture of genes detected in activated T cells
(overlap of 559 genes between activated T cells and PBMCs)
and genes which are not detected in purified T-cell
preparations (571 genes), many of which are associated with
myeloid cells. Several of the highly upregulated genes unique
to PBMC cultures, for example, matrix metalloproteinase-12
(MMP-12) and CCL18 (Table S2), are gene products, which
are detected in myeloid dendritic cells and that are not
typically associated with T cells (Schutyser et al., 2001; Rust
et al., 2006). We interpret these data as being consistent with
paracrine effects of T-cell-derived cytokines on blood
monocytes that are present in PBMC preparations.
As gene products of myeloid cells are highly upregulated
in psoriasis skin lesions (Zhou et al., 2003a, b), we believe
that the PBMC system better reflects T-cell/myeloid cell
interactions that may occur in autoimmune inflammation in
peripheral tissues.
Identification of genes regulated by cytokine-neutralizing
antibodies in activated PBMC cultures
To define the gene that are regulated by cytokines, we used
the approach of measuring changes in gene expression in
PBMCs in the presence of available antibodies that block
cytokines like TNF or IFNg. These antibodies bind to TNF or
IFNg produced after activation of T cells in PBMCs and thus
inhibit the expression of genes that are regulated by these
cytokines. These antibodies consist of two domains, one that
neutralizes the cytokines and another nonspecific IgG1
domain. To ascertain the contribution of the cytokine-binding
domain to broad gene activation that occurs in activated
PBMCs, we first compared the gene expression in stimulated
PBMCs with control humanized IgG1 that lacked relevant
antigen specificity. As shown in the heat map in Figure 2a
and Table S3, there were seven genes that were modestly
(41.2-fold) downregulated by treatment with the control
antibody, but none by41.5-fold. We therefore, used the cut-
off of 1.5-fold difference to define the effects of therapeutic
antibodies in stimulated PBMCs.
Identification of genes suppressed by blocking IFNc in activated
PBMC cultures
We then proceeded to study the suppression of inflammatory
genes with humanized or chimeric cytokine antibodies that
have been used in clinical trials of patients with a variety of
inflammatory diseases to block IFNg or TNF. Consistent with
cell activation and viability measures, addition of cytokine-
blocking antibodies did not significantly affect expression of
most activation-associated genes (B80% were unchanged).
Stimulated genes selected as being cytokine-regulated
had expression reduced by at least 1.5-fold, with a P-value
o0.01. The IFNg-regulated genes identified by this approach
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Figure 1. T-cell activation, apoptosis, detection of IFNc on T cells, and effects on T cells, B cells, and NK cells. PBMC stimulation with anti-CD3/CD28
antibody (S) was compared with non-stimulated PBMCs (NS), activation in the presence of anti-IFNg antibody (fontolizumab) and anti-TNF antibody
(infliximab). Representative plots out of four individual experiments are presented. (a) T-cell activation: percentage of expression of CD3/CD69-positive T cells
is indicated in the upper right-hand corner of dot plots. (b) Apoptosis: percentage of propidium iodide/annexinV-FITC-positive cells is indicated in the
upper right-hand corner of the dot plots. (c) Intracellular IFNg positive T-cell measurements: percentage of expression of CD3/IFNg-positive T cells indicated
in the upper right-hand corner of dot plots. (d) Effects on T cells, B cells, and NK cells: percentages of lymphocytes (CD3þ T cells, CD3CD19þ B cells,
and CD3CD56þCD16þ NK cells) are presented as column bars.
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correspond to genes previously identified in other cell types
as being IFNg regulated, through exposing those cells directly
to IFNg in vitro (Boehm et al., 1997; Banno et al., 2003). We
identified several genes that have not been previously
associated with regulation by TNF (gene symbols are in bold
inTables 2 and 3) when compared with studies defining TNF-
regulated genes (Schwamborn et al., 2003; Zhou et al.,
2003a) in cell lines.
Figure 2a shows clear blocks of genes that are suppressed
by IFNg or TNF blockade after these selection criteria. There
are genes exclusively suppressed by blocking IFNg or TNF,
but also a few genes that are blocked by fontolizumab or
infliximab. Nine genes were exclusively suppressed by
fontolizumab (anti-IFNg) (Table 2a), while another seven
genes were blocked by both fontolizumab and infliximab
(Table 2b). Interestingly, IFNg mRNA was among the highest
regulated genes, with its mRNA suppressed by seven-fold
(detected by microarray analysis or four-fold (detected by
real-time reverse transcription-PCR analysis) in fontolizumab-
treated cultures (Table 2b; Figure 2b). In addition, very low
levels of IFNg protein were detected in fontolizumab-treated
cultures (Figure 3), but this effect is due to neutralization of
secreted cytokine by fontolizumab. Furthermore, IL-12
receptor (IL-12Rb2) mRNA was suppressed by 6.4-fold in
these cultures (Figure 2b). Strong suppression of IL-1a and IL-
1b proteins is shown in Figure 3. We also detected a B30%
reduction in the number of T cells synthesizing IFNg protein,
as detected by intracellular cytokine staining (Figure 1c). This
approach seems to faithfully identify IFNg-regulated genes, as
there is a good overlap between identified genes with those
previously associated with IFNg regulation.
Identification of genes suppressed by blocking TNF in activated
PBMC cultures
Infliximab, which is a chimeric (mouse/human) antibody-
binding TNFa, was used to block TNF in anti-CD3/CD28-
stimulated PBMC cultures. This antibody was chosen, as it
has been the most commonly used TNF inhibitor in treatment
of inflammatory diseases in humans. However, some
previous reports have suggested that infliximab induces
apoptosis in activated leukocytes (van den Brande et al.,
2005). Since our gene expression measures assume func-
tional blockade of cytokine signaling, rather than killing of
lymphocyte populations, we assessed cell viability in
infliximab-treated cultures by annexinV/propidium iodide
staining (Figure 1b). As shown in this figure, T-cell activation
occurred in a normal manner in PBMCs cultured with
infliximab and no increase in apoptosis was measured by
annexinV/PI staining. Other experiments gating on B cells or
NK cells showed no induction of apoptosis in these cell
populations (Figure 1d). Overall cell recovery and total RNA
amounts obtained from infliximab-treated cultures were not
significantly reduced from other cultures that were included
as controls.
As shown by the heat maps in Figure 2a, TNF blockade
with infliximab reduces expression of a much larger set of
stimulated genes compared with IFNg blockade. Overall, 50
genes (all genes are listed in Table S4) were significantly
suppressed by41.5-fold (Po 0.01) by infliximab. Genes that
were exclusively suppressed by infliximab (Table 2c)
included MMP-12 and IL-1b, which are known to be
regulated by TNF/NF-kB. However, IFNg mRNA was also
strongly suppressed by infliximab (Table 2b, B9.5-fold
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Figure 2. mRNA analysis. (a) Heat maps of activation genes regulated by
IFNg, TNF. mRNA from cultured PBMCs was hybridized to individual
oligonucleotide arrays containing B12,000 human genes (Affymetrix HG-
U95Av2 chips). Heat maps show unsupervised hierarchical clusters of genes
regulated by TNF or IFNg in PBMCs by 41.5-fold, using similarity measure,
Pearson correlation. Gene lists were created after significance analysis as
described in Materials and Methods. The mean expression levels of genes
regulated by 41.5-fold are represented by red lines (upregulated) and green
lines (downregulated). Genes in PBMCs activated with anti-CD3/CD28
(stimulated) are compared with non-stimulated, stimulated in the presence of
control antibody (IgG1), TNF inhibitor infliximab and IFNg inhibitor
fontolizumab. Genes exclusively regulated by 41.5-fold by either infliximab
or fontolizumab are listed in Table 2 and complete lists of genes, with fold
changes and P-values, and confidence intervals in Table S4 and Table S5.
(b) Real-time reverse transcription-PCR confirmation of IL-12Rb2, IFNg, and
IL-8. mRNA from PBMCs stimulated with anti-CD3/CD28 antibody (S) was
compared with non-stimulated PBMCs (NS), activation in the presence of
anti-IFNg antibody (fontolizumab, F), anti-TNF antibody (infliximab, I). Mean
of relative mRNA expression normalized to human acidic ribosomal protein is
plotted as column bars (n¼ 3).
658 Journal of Investigative Dermatology (2008), Volume 128
AS Haider et al.
Role of TNF in Autoimmune Diseases
reduction), and suppression to this extent was not expected.
As shown in Figure 2b, reduced mRNA for IFNg led to a large
reduction in IFNg protein synthesis in infliximab-treated
PMBC cultures (Figure 3). As an independent measure of IFNg
synthesis by T cells, cytokine levels were determined by
intracellular cytokine staining in infliximab-treated cultures.
Infliximab treatment reduced the number of IFNg-positive T
cells by 59% and, in addition, reduced the amount of IFNg
protein produced (as assessed by mean fluorescence intensity
measures; Figure 1c). However, many genes, which are not
regulated by IFNg, are also suppressed by infliximab (Table
2c). It thus appears that gene sets regulated by infliximab
partly overlap with genes regulated by IFNg (Table 2b), but
the majority of TNF-regulated genes are distinct from IFNg-
regulated genes. Suppression of genes such as MMP-12,
CCL17, CCL18, and CCL20 suggest that TNF formed by
activated T cells is acting in a paracrine manner to stimulate
genes in monocytes or myeloid dendritic cells that are
contained in PBMC cultures.
New insights into pathogenesis of psoriasis
Psoriasis is an inflammatory skin disease in which mRNAs for
many inflammatory gene products are upregulated, as
detected via array-based approaches or by real-time reverse
transcription-PCR . For example, a large set of genes, which
are characteristic of cellular responses to IFNs are present in
skin lesions, and these products can potentially explain
activation of several cell types involved in this disease
process (Zhou et al., 2003b). Although TNF antagonists have
emerged as effective therapeutics for patients with psoriasis,
the role of TNF in disease pathogenesis is much less clear
with respect to inflammatory pathways. In this study using
Table 1. Genes upregulated in activated PBMCs
Stimulated versus non-stimulated P-valueo0.01)
Gene ID Symbol Gene product Fold increase LowF HighF
1611_s_at IFNg Homo sapiens interferon-gamma (IFNG) gene 12.5 3.3 47.6
1534_at IL-12RB2 Interleukin 12 receptor, beta 2 7.3 3.5 15.4
1481_at MMP-12 Matrix metalloproteinase 12 (macrophage elastase) 6.8 1.2 38.7
39802_at MCP-3 Homo sapiens mRNA for monocyte chemotactic protein-3 4.6 0.8 25.2
37823_at CCL8 Chemokine (C–C motif) ligand 8 4.3 2.0 9.4
408_at CXCL1 Human gene for melanoma growth stimulatory activity
(MGSA)
4.2 2.0 8.6
38299_at IL-6 Interleukin 6 (interferon, beta 2) 3.2 1.2 8.4
1702_at IL-2RA Interleukin 2 receptor, alpha 3.1 2.1 4.8
40385_at CCL20 Chemokine (C–C motif) ligand 20 3.1 1.3 7.3
36296_at LTA Lymphotoxin alpha (TNF superfamily, member 1) 2.6 2.0 3.4
39402_at IL-1B Interleukin 1, beta 2.5 1.5 4.2
1369_s_at IL-8 Human interleukin 8 (IL-8) gene, complete cds 2.4 1.9 3.1
38326_at G0S2 Human G0S2 protein gene, complete cds 2.4 1.8 3.3
34037_at IL-9 Interleukin 9 2.4 1.8 3.1
1852_at TNF Human gene for tumor necrosis factor (TNF-alpha) 2.2 1.5 3.1
32128_at CCL18 Chemokine (C–C motif) ligand 18 2.2 1.5 3.1
34916_s_at TNFRSF4 Tumor necrosis factor receptor superfamily, member 4 2.1 1.7 2.7
41592_at SOCS1 Suppressor of cytokine signaling 1 2.1 1.6 2.9
34022_at CXCL3 Chemokine (C–X–C motif) ligand 3 2.1 1.2 3.9
37137_at GZMB Serine protease-like protein precursor 2.1 1.9 2.4
668_s_at MMP-7 Human matrilysin gene, exon 6 and complete cds 2.1 1.2 3.6
436_at IL-5 Interleukin 5 (colony-stimulating factor, eosinophil) 2.0 1.5 2.7
41677_at IL-15RA Interleukin 15 receptor, alpha 1.9 1.6 2.4
37014_at MX1 Interferon-inducible protein p78 (mouse) 1.9 1.4 2.5
36377_at IL-18R1 Interleukin 18 receptor 1 1.7 1.5 2.0
34021_at IL-2 Interleukin 2 1.6 1.0 2.6
PBMC, peripheral blood mononuclear cell.
Selected list of genes (top 25) upregulated after stimulation of PBMCs with anti-CD3/28 (stimulated) for 24 hours, as compared with non-stimulated PBMCs.
Fold change are mean expression values of stimulated versus non-stimulated, with corresponding confidence intervals (LowF and HighF); Po0.01. Complete
lists with P-values, fold changes, and confidence intervals are online in Table S1. Gene symbols and products are described in Gene Ontology annotations.
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Table 2. Genes regulated by IFNc inhibitor (fontolizumab) and/or TNF inhibitor (infliximab)
a. Genes suppressed by fontolizumab
Stimulated versus infliximab Stimulated versus fontolizumab (Po0.01)
Gene ID Symbol Gene product P-value
Fold
change LowF HighF P-Value
Fold
decrease LowF HighF
39802_at MCP-3 Homo sapiens mRNA for
monocyte chemotactic
protein-3
0.2500 2.6 0.6 11.8 0.0156 2.9 0.8 10.6
37823_at CCL8 Chemokine (C-C motif)
ligand 8
0.0625 2.0 1.0 3.9 0.0156 4.5 2.3 8.7
41677_at IL-15RA Interleukin 15 receptor,
alpha
0.0156 1.5 1.4 1.6 0.0156 1.7 1.6 1.9
1440_s_at TNFRSF6 Tumor necrosis factor
receptor superfamily,
member 6
0.0156 1.5 1.2 1.7 0.0156 1.6 1.3 2.0
38299_at IL-6 Interleukin 6 (interferon,
beta 2)
0.0625 1.4 1.0 2.0 0.0156 2.2 1.0 4.9
38549_at cig5 Viperin 0.1406 1.2 0.9 1.7 0.0156 2.5 2.0 3.1
37014_at MX1 Myxovirus (influenza virus)
resistance 1
0.1094 1.2 0.9 1.5 0.0156 1.6 1.4 1.9
1107_s_at G1P2 Interferon, alpha-inducible
protein (clone IFI-15K)
0.2031 1.1 0.9 1.4 0.0156 1.6 1.4 1.8
626_s_at IFI35 Interferon-induced protein
35
0.2344 1.1 0.9 1.3 0.0156 1.6 1.5 1.7
35095_r_at LILRA3 Leukocyte
immunoglobulin-like
receptor
0.2969 1.1 0.9 1.3 0.0156 1.5 1.1 2.0
b. Genes commonly suppressed by fontolizumab and infliximab
Stimulated versus infliximab (Po0.01) Stimulated versus fontolizumab (Po0.01)
Gene ID Symbol Gene product P-Value Fold
decrease
LowF HighF P-value Fold
decrease
LowF HighF
1611 _s_at IFNc Homo sapiens interferon-
gamma (IFNG) gene,
complete cds
0.0156 9.5 3.1 29.2 0.0156 7.0 2.0 24.6
1534_at IL-12RB2 Interleukin 12 receptor,
beta 2
0.0156 5.5 3.0 10.0 0.0156 4.9 2.6 9.4
408_at CXCL1 Human gene for melanoma
growth stimulatory activity
(MGS
0.0156 2.8 1.6 4.8 0.0156 3.2 1.9 5.4
36776_at LAG3 Lymphocyte-activation
gene 3
0.0156 2.3 1.2 4.4 0.0156 1.8 1.2 2.8
33849_at PBEF1 Pre-B-cell colony
enhancing factor 1
0.0156 1.6 1.3 2.0 0.0156 1.6 1.4 1.9
32868_at TGM3 Transglutaminase 3 0.0156 1.6 1.2 2.0 0.0156 1.7 1.2 2.4
1852_at TNF Human gene for tumor
necrosis factor (TNF-alpha).
0.0156 1.5 1.3 1.9 0.0156 1.5 1.2 1.9
c. Genes suppressed by infliximab
Stimulated versus infliximab (Po0.01) Stimulated versus fontolizumab
Gene ID Symbol Gene product P-Value Fold
decrease
LowF HighF P-Value Fold
change
LowF HighF
1482_g_at MMP12 Matrix metalloproteinase 12
(macrophage elastase)
0.0156 5.3 1.0 29.2 0.0156 0.3 0.1 0.7
1702_at IL-2RA Interleukin 2 receptor,
alpha
0.0156 2.3 1.7 3.1 0.0469 1.5 1.0 2.1
39402_at IL-1B Interleukin 1, beta 0.0156 2.2 1.5 3.2 0.3906 0.9 0.8 1.1
1520_s_at EDN1 Homo sapiens endothelin-1
(EDN1) gene, complete cds.
0.0156 2.1 1.5 3.0 0.4844 1.0 0.8 1.1
Table 2 continued on the following page
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38326_at G0S2 Human G0S2 protein gene,
complete cds.
0.0156 2.0 1.6 2.6 0.0938 0.7 0.4 1.1
40385_at CCL20 Chemokine (C-C motif)
ligand 20
0.0156 2.0 1.2 3.3 0.2188 1.3 0.8 2.1
32128_at CCL18 Chemokine (C-C motif)
ligand 18
0.0156 1.9 1.5 2.5 0.0313 0.4 0.2 0.8
1183_at CCL17 Chemokine (C-C motif)
ligand 17
0.0156 1.9 1.3 2.9 0.0156 0.0 0.0 0.3
34037_at IL-9 Interleukin 9 0.0156 1.9 1.5 2.3 0.0156 0.6 0.6 0.7
37485_at SLC27A2 Solute carrier family 27
(fatty acid transporter),
member 2
0.0156 1.9 1.6 2.1 0.0156 1.5 1.3 1.7
544_at NFKB2 Nuclear factor of kappa 2 0.0156 1.8 1.3 2.5 0.0156 1.2 1.1 1.5
1983_at CCND2 Cyclin D2 0.0156 1.8 1.5 2.0 0.0156 1.4 1.3 1.6
38909_at CYP27B1 Cytochrome P450, family
27, subfamily B,
polypeptide 1
0.0156 1.7 1.4 2.1 0.0313 1.2 1.1 1.3
31853_at EED Embryonic ectoderm
development
0.0156 1.7 1.5 1.9 0.0156 1.2 1.1 1.4
36296_at LTA Lymphotoxin alpha (TNF
superfamily, member 1)
0.0156 1.7 1.5 2.0 0.0156 1.2 1.1 1.3
436_at IL-5 Interleukin 5 (colony-
stimulating factor,
eosinophil)
0.0156 1.7 1.4 2.2 0.7500 1.0 0.9 1.1
33513_at SLAMF1 Signaling lymphocytic
activation molecule family
member 1
0.0156 1.7 1.4 2.1 0.0156 1.4 1.2 1.6
39827_at DDIT4 DNA-damage-inducible
transcript 4
0.0156 1.7 1.4 2.1 0.3281 1.1 0.9 1.3
39120_at MT1X Metallothionein 1X 0.0156 1.7 1.2 2.3 0.0156 1.4 1.1 1.7
1788_s_at DUSP4 Dual specificity
phosphatase 4
0.0156 1.7 1.3 2.2 0.0625 1.2 1.0 1.5
1536_at CDC6 CDC6 cell division cycle 6
homolog (S. cerevisiae)
0.0156 1.7 1.4 1.9 0.0625 1.2 1.0 1.5
37282_at MAD2L1 MAD2 mitotic arrest
deficient-like 1 (yeast)
0.0156 1.6 1.2 2.1 0.2031 1.2 0.9 1.5
32186_at SLC7A5 Solute carrier family 7,
member 5
0.0156 1.6 1.3 2.0 0.0156 1.3 1.1 1.5
34916_s_at TNFRSF4 Tumor necrosis factor
receptor superfamily,
member 4
0.0156 1.6 1.4 1.8 0.5625 1.0 0.9 1.2
37137_at GZMB Serine protease-like protein
precursor
0.0156 1.6 1.4 1.8 0.0156 1.2 1.1 1.3
31540_at TNFRSF9 Tumor necrosis factor
receptor superfamily,
member 9
0.0156 1.6 1.4 1.8 0.1406 0.8 0.5 1.1
1369_s_at IL-8 Human interleukin 8 (IL8)
gene, complete cds.
0.0156 1.6 1.3 1.8 0.0156 1.4 1.3 1.4
494_at IL-13 Human interleukin-13 (IL-
13) precursor gene,
complete cds.
0.0156 1.6 1.1 2.3 0.5156 1.1 0.9 1.4
849_g_at TRAF1 TNF receptor-associated
factor 1
0.0156 1.5 1.4 1.7 0.0313 1.1 1.0 1.3
39942_at BATF Homo sapiens B-ATF gene,
complete cds.
0.0156 1.5 1.3 1.8 0.0156 1.2 1.1 1.4
33812_at ADAM19 A disintegrin and
metalloproteinase domain
19 (meltrin beta)
0.0156 1.5 1.3 1.8 0.8281 1.0 0.8 1.4
Table 2. cotinued
c. Genes suppressed by infliximab
Stimulated versus infliximab (Po0.01) Stimulated versus fontolizumab
Gene ID Symbol Gene product P-Value
Fold
decrease LowF HighF P-Value
Fold
change LowF HighF
Table 2 continued on the following page
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very stringent criteria, we have identified a set of six genes
that are exclusively IFNg regulated as compared with 15 TNF-
regulated inflammatory genes in leukocytes that are also
upregulated in psoriasis lesions (Table 3). Hence, a strong
genomic signal for TNF can be associated with psoriasis
lesions. In considering pathogenic roles for TNF in inflam-
matory diseases, including psoriasis, much emphasis has
been placed on its role in inducing ‘‘immediate’’ genes (IL-1,
IL-6, and IL-8) that regulate innate immune responses to
potential pathogens (Dinarello et al., 1986). Although these
are important inflammatory cytokines, the way in which TNF
could serve to regulate a complex cellular infiltrate that
contains several types of dendritic cells and T-cell subsets is
not readily explained by this trio of cytokines. Our data show
that infliximab strongly downregulates key chemokines (eg,
CCL20/MIP-3a; Table 2c) that control dendritic cell and T-
cell infiltration into peripheral tissues, and key effector
molecules (IL-1b, IL-8, granzyme B) of T cells and/or NK
cells. In addition, infliximab suppresses several cell surface
receptors (Table 3, for example, IL-12R that lead to activation
and differentiation of T-cell subsets implicated in psoriasis).
To the extent that TNF appears to serve as a strong inducer of
IFNg production by T-cells, and that infliximab also regulates
many classical IFN response genes, much of the therapeutic
activity of infliximab in psoriasis might be through suppres-
sion of the IL-23/g-IFN-regulated ‘‘Type-1’’ pathway (Kim
et al., 2004). Hence, in a chronic inflammatory disease, the
pathogenic activities of TNF may be much more associated
with cellular infiltrates and inflammatory products of the
adaptive arm of immunity, rather than those of an ‘‘im-
mediate’’ innate response.
DISCUSSION
We have pursued identification of inflammatory (leukocyte
derived) genes that are regulated when activated cells are
exposed to antibodies that neutralize IFNg or TNF. In part, the
impetus for this work has been to derive a better under-
standing of how specific cytokines may contribute to
inflammation in an array of cell-mediated ‘‘autoimmune
diseases’’ like psoriasis vulgaris, inflammatory bowel disease,
and rheumatoid, or psoriatic arthritis. Infliximab was chosen
as the model TNF-neutralizing antibody, since it has shown
effectiveness in reversing inflammation in each of these
conditions (Chaudhari et al., 2001; Reich et al., 2005).
However, very little is known about the therapeutic
mechanism of infliximab in humans, even though it has
been administered to 4200,000 people with an array of
autoimmune inflammatory diseases. One of the potential
paradoxes in the treatment of psoriasis with infliximab is that
psoriasis has a very strong signature of upregulated genes that
can be assigned to IFN-induced signaling (Zhou et al., 2003b;
Lew et al., 2004), but the number of induced genes that can
be assigned to TNF/NF-kB signaling is quite small. Further-
more, psoriasis is strongly associated with cutaneous
infiltrates of Type-1 T cells (defined by secretion of IFNg),
and the array of activated genes strongly implies T cells are
acting as pathogenic activators in this disease. Thus, there is
little direct evidence that TNF serves as a pathogenic cytokine
in psoriasis. In trying to explain therapeutic activity of TNF
inhibitors in human inflammatory diseases, numerous in-
vestigators have promoted the view that beneficial effects of
TNF inhibitors are likely to be mediated by modulating
pathways of innate immunity, which in turn, are strongly
41439_at MYO1B Myosin IB 0.0156 1.5 1.3 1.8 0.0156 0.8 0.7 1.0
572_at TTK Human kinase (TTK)
mRNA, complete cds.
0.0156 1.5 1.3 1.8 0.0313 1.2 1.0 1.3
40357_at INHBA Inhibin, beta A (activin A,
activin AB alpha
polypeptide)
0.0156 1.5 1.3 1.9 0.1719 1.2 0.9 1.6
1461_at NFKBIA Nuclear factor of kappa
inhibitor, alpha
0.0156 1.5 1.4 1.7 0.0625 1.1 1.0 1.2
35992_at MSC Musculin (activated B-cell
factor-1)
0.0156 1.5 1.2 1.9 0.0469 0.8 0.6 0.9
36909_at WEE1 WEE1 homolog (S. pombe) 0.0156 1.5 1.3 1.8 0.0938 1.1 1.0 1.4
TNF, tumor necrosis factor.
List of genes, which are downregulated by 41.5-fold after treatment of activated PBMCs with a. IFNg inhibitor, fontolizumab exclusively; b. IFNg
inhibitor fontolizumab and TNF inhibitor, infliximab; and c. TNF inhibitor, infliximab, exclusively corresponding to the heat map in Figure 2a. Fold decreases
are mean expression values of stimulated versus treated with fontolizumab, or infliximab with corresponding confidence intervals (LowF and HighF) and
P-values. Gene symbols and products are described in Gene Ontology annotations. Full lists of all genes regulated by infliximab and fontolizumab
are available in Table 4S and Table 5S, respectively. Genes in bold have not been previously associated with regulation by IFNg or TNF.
Table 2. cotinued
c. Genes suppressed by infliximab
Stimulated versus infliximab (Po0.01) Stimulated versus fontolizumab
Gene ID Symbol Gene product P-Value
Fold
decrease LowF HighF P-Value
Fold
change LowF HighF
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linked to tissue infiltration by neutrophils and other leuko-
cytes of the innate immune system (De Rycke et al., 2005;
Pay et al., 2005). In contrast, our data suggest that TNF
blockade could have major regulatory effects on adaptive
immune responses by suppressing synthesis of IFNg and the
b2 subunit of the IL-12R, as well as other T-cell-derived gene
products. Note that the IL-12R functions to promote Th1
polarization of T cells and also the level of IFNg synthesis by
T cells. Hence, suppression of the IL-12Rb2 subunit might
control the measured decrease in IFNg synthesis by inflix-
imab.
The data presented in this study significantly expand the
roster of genes, which are regulated (directly or indirectly) by
TNF. We acknowledge that these data are derived from
samples of only eight subjects, and could limit findings some
relevant associations. Study of larger populations might
demonstrate statistical significance to some genes now
excluded or variations in individual responses might be
appreciated, accounting for variability in clinical responses to
cytokine antagonists.
In contrast to human keratinocytes, where IFNg regulates
many more genes than TNF (Banno et al., 2003, 2004), our
results in activated PBMCs suggest that TNF regulates many
more genes than IFNg in leukocytes. The set of genes, which
are suppressed by infliximab strongly argues that TNF may
play a key role in stimulating T cells, and thus effector
pathways, which are generally assigned to adaptive immune
responses. The strong suppression of IFNg, arguably the key
Table 3. Overlap between genes upregulated in psoriasis lesions and cytokine-regulated genes in leukocytes
Systematic LS/NL
Regulated
by Symbol Gene product
Lesional (LS) versus non-lesional
(NL) fold change (LS/NL)
38549_at 5.443 IFNg MX1 Myxovirus (influenza virus) resistance 1, 7.0
626_s_at 1.493 IFNg G1P2 Interferon, alpha-inducible protein (clone IFI-15K) 5.7
41677_at 1.257 IFNg Cig5 Viperin 5.4
1520_s_at 2.138 IFNg IFI35 Interferon-induced protein 35 1.5
33513_at 1.377 IFNg IL-15RA Interleukin 15 receptor, alpha 1.3
34916_s_at 1.275 IFNg CCL8 Chemokine (C–C motif) ligand 8 1.2
1107_s_at 5.667 TNF CCL20 Chemokine (C–C motif) ligand 20 7.1
37823_at 1.242 TNF IL-8 Human interleukin 8 (IL-8) gene, complete cds. 5.1
32868_at 3.926 TNF MMP-12 Matrix metalloproteinase 12 (macrophage elastase) 3.2
1534_at 1.361 TNF GZMB Serine protease-like protein precursor 2.5
40385_at 7.093 TNF IL-1B Interleukin 1, beta 2.2
1369_s_at 5.139 TNF EDN1 Homo sapiens endothelin-1 (EDN1) gene, complete
cds.
2.1
1481_at 3.24 TNF SLC7A5 Solute carrier family 7 2.0
37137_at 2.487 TNF TTK Human kinase (TTK) mRNA, complete cds. 1.9
39402_at 2.247 TNF CDC6 CDC6 cell division cycle 6 homolog (S. cerevisiae) 1.9
32186_at 1.957 TNF MAD2L1 MAD2 mitotic arrest-deficient-like 1 (yeast) 1.5
572_at 1.877 TNF MYO1B Myosin IB 1.5
1536_at 1.86 TNF BATF Homo sapiens B-ATF gene, complete cds. 1.4
1721_g_at 1.487 TNF SLAMF1 Signaling lymphocytic activation molecule family
member 1
1.4
39942_at 1.387 TNF TNFRSF4 Tumor necrosis factor receptor superfamily, member 4 1.3
33812_at 1.224 TNF ADAM19 A disintegrin and metalloproteinase domain 19 (meltrin
beta)
1.2
37014_at 6.977 TNF+IFNg CXCL1 Human gene for melanoma growth stimulatory activity
(MGSA).
14.0
408_at 14.02 TNF+IFNg PBEF1 Pre-B-cell colony enhancing factor 1 4.2
33849_at 4.154 TNF+IFNg TGM3 Transglutaminase 3 3.9
41439_at 1.459 TNF+IFNg IL-12RB2 Interleukin 12 receptor, beta 2 1.4
Psoriasis genes, which are regulated by IFNg or TNF.
Genes that are downregulated (41.5-fold) after inhibition of IFNg with fontolizumab or TNF with infliximab in stimulated PBMCs were compared with genes
upregulated in psoriasis lesions, as compared with non-lesional skin biopsies (Zhou et al., 2003a,b). Fold change are mean expression values in lesional (LS)
versus non-lesional (NL) skin biopsies. Gene symbols and products are described in Gene Ontology annotations.
TMF, tumor necrosis factor.
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cytokine produced by activated Th1 T cells, in infliximab-
treated PBMCs suggests that important regulatory/effector
cytokines of T cells are modulated by TNF within an
inflammatory environment. While prior work has established
that TNF can serve as co-stimulus of T-cell activation
(Banerjee et al., 2005), and also that NF-kB-binding sites
are present in the promoter of the IFNg gene (Sica et al.,
1997), the extent to which infliximab suppresses IFNg levels
in PBMC cultures and particularly in CD3þ T cells was
unexpected and is a surprising result of this study. The
consequences of reducing IFNg synthesis in T cells are many.
Relevant outcomes could be significant impairment of
macrophage activation for killing of intracellular organisms
(Marodi et al., 1993).
The relevance of our findings to clinical administration of
TNF inhibitors is suggested by two observations. First,
treatment of psoriasis with etanercept, a fusion protein that
neutralizes TNF and lymphotoxin, does lead to gradual
reductions in levels of IFNg mRNA in skin lesions, as well as
reductions in IFNg-induced gene products such as the
chemokines MIG and IP-10 (Gottlieb et al., 2005). The gene
Mx-1 has been identified to be regulated by type I IFNs as
well as type 2 IFNg (Banno et al., 2003; Pletneva et al., 2006).
Mx-1 is suppressed in psoriasis lesions by etanercept, in
parallel with reductions in IFNgmRNA (Gottlieb et al., 2005).
We acknowledge that the effects may also be derived from
regulation of type 1 IFNs that are also present in psoriasis.
Hence, there is in vivo evidence that TNF inhibition can
suppress or cross-regulate cytokine response pathways that
are considered to be hallmarks of the adaptive immune
system. Secondly, direct suppression of IFNg synthesis in T
cells by infliximab could explain cases of severe mycobac-
terial infection and/or reactivation of tuberculosis in patients
undergoing treatment with infliximab (Keane et al., 2001).
Our results thus suggest that pathways, which regulate innate
responses (suppression of IL-8, TNF, or IL-1), as well as
effector responses of T cells associated with adaptive
immunity, are likely to be suppressed by infliximab. In
contrast, inhibition of IFNg with fontolizumab leads to more
restricted suppression of genes and most suppressed genes
have been previously assigned to IFNg responses in an array
of individual cell types (Boehm et al., 1997). Although there
is some overlap in gene sets derived by inhibiting IFNg versus
TNF, clear sets of genes that are uniquely regulated by each
inhibitor can be identified. In turn, these gene sets can be
applied to help interpret cytokine-associated genomic signals
in complex inflammatory diseases like psoriasis. Please note
that our cytokine response gene sets are not specific to
psoriatic leukocytes, as we sought to derive generalizable
expression profiles that could be used to study many different
inflammatory diseases. However, since response of psoriatic
leukocytes to TNF or IFNg might differ, for example, as an
effect of varying psoriasis susceptibility (PSORS) genes in
different individuals, and since psoriatic T cells may be more
activated (Cooper et al., 2003), it would be interesting to
eventually compare genomic responses of normal versus
psoriatic leukoctyes with therapeutic cytokine inhibitors.
Furthermore, there could be key differences in induced gene
sets between responding and non-responding psoriasis
patients to a given inhibitor, as we have recently demon-
strated for alefacept (Haider et al., 2007).
In the previous work, we have identified B1,300 genes
upregulated in psoriasis skin lesions (Zhou et al., 2003b), but
very few genes could be assigned to TNF or NF-kB-regulated
pathways. This study identifies 18 genes that are over-
expressed in psoriasis, which are suppressed by infliximab in
PBMCs (Table 3). Accordingly, a significant ‘‘signal’’ for TNF-
regulated genes can now be assigned to psoriasis vulgaris.
MATERIALS AND METHODS
Samples used in the study
Institutional review board approval was obtained before inviting
healthy volunteers to participate in the study. Informed consent was
obtained from volunteers before their participation, and the study
was performed with strict adherence to the Declaration of Helsinki
Principles. PBMCs from seven donors and T cells from three donors
were isolated from freshly drawn human blood (in heparin tube)
using Ficoll-Paque Plus, according to standard protocol. T cells were
negatively isolated using Dynals T-cell negative isolation kit (Dynal
Biotech, Invitrogen Corp, Carlsbad, CA, cat. no. 113-11D) according
to the manufacturer’s protocol. PBMCs and T cells were resuspended
at 1 106 cells/ml in Roswell Park Memorial Institute (Invitrogen
Corp, Carlsbad, CA, cat. no 21870)þ 5% heat-inactivated human
serum (Hyclone, Logan, UT, SH30071.03,) and PenStrep (penicillin
10KU/ml, streptomycin 10mg/ml; Invitrogen, cat. no. 15140-148).
Cultures were set up in 20ml per dish (35 20mm; Corning, NY,
cat. no. 25020). In cultures with PBMCs, monocytes were allowed to
adhere for 1 hour at 371C before activation and addition of
inhibitors.
Non-stimulated PBMCs or T cells (NS) served as control to
stimulation (S) with anti-CD3/CD28 using Dynabeadss CD3/CD28
T-Expander (Dynal Biotech, 111.31). PBMCs were also stimulated in
the presence of IFNg inhibitor fontolizumab (F) (100 g/ml, HuZAFTM,
anti-IFNg, PDL Biopharma), TNF inhibitor, infliximab (I) (100 g/ml,
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Figure 3. Protein expression of IL-1a and IL-1b, IFNc and TNF. Cytokine
levels in the supernatant from PBMCs activated with anti-CD3/CD28 antibody
(S) were compared with non-stimulated PBMCs (NS), activation in the
presence of anti-IFNg antibody (fontolizumab, F) or anti-TNF antibody
(infliximab, I). Mean of cytokine expression is plotted as column bars (n¼ 3).
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Remicades, anti-TNF, Centocor), and the control IgG1 antibody
MSL109 (200 g/ml, PDL Biopharma). All reagents were added at time
0 and cells (adherent and floating) and supernatant were collected at
24 hours post-stimulation. Cytokines/chemokine levels were mea-
sured in the supernatant and the cells were lysed and stored at at
801C for later RNA preparation, as described previously (Haider
et al., 2006).
The description for the following measurements are available
online in the Supplementary material for Materials and Methods:
1. Measurement of IFNg, IL-1a, IL-1b and TNF level by Luminex.
2. PBMC phenotype and apoptosis.
3. Real-time reverse transcription-PCR and microarray analysis of
tissue mRNA gene expression.
4. Statistical comparisons of microarray analysis.
Complete lists of genes with P-values, fold changes in mean
expression values, upper and lower confidant intervals (F-upper,
F-lower), and description of relevant functions of genes are provided
in Tables S1–S6 (see http://www.rockefeller.edu/labheads/krueger/
supplemental)
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